Moderate to Persistent Asthma in the Obese Subject
Status:
Terminated
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
Obesity is associated with increased airway inflammation and asthma severity that results in
suboptimal control of asthma despite therapy with high dose inhaled corticosteroids (ICS).
The investigators suggested that the addition of Singular (montelukast)[LTRA] to moderate
doses of inhaled corticosteroids will improve asthma control. This cross over study will be
treat subjects with moderate dose ICS/LTRA for 12 weeks and high dose ICS with placebo for 12
weeks.